Johnson & Johnson announced its acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system (CNS) disorders.

In 2024, the range of diseases treated by globally approved new drugs was diverse, with cancer and rare diseases leading in the total number of new drug approvals.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction.

The siRNA therapeutics market is expected to grow substantially from $12.7 billion in 2022 to $39.2 billion by 2029.

In an era characterized by information overload, effectively managing and utilizing vast amounts of biomedical data has become another pressing issue.

In recent years, a molecular target known as Claudin18.2 has emerged as a prominent target in the treatment of gastric cancer, pancreatic cancer, and various other solid tumors.

the Antibody-Drug Conjugates (ADCs) market has entered a new phase of rapid growth since 2019, maintaining an annual growth rate exceeding 30%.

Currently, only three CXCR4 (C-X-C motif chemokine receptor 4) antagonists have been approved globally: Plerixafor, Motixafortide, and Mavorixafor.

the siRNA therapeutics market is projected to grow substantially from $12.7 billion in 2023 to $39.2 billion by 2029.

According to a report by Yole Développement, the CRISPR technology market is projected to reach $5 billion by 2023.

The global stem cell therapy market was valued at $10–12 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10–15%.

The application of AI technology in new drug development spans several critical stages, from compound synthesis to drug repurposing.